Vutiglabridin

SKU: orb1688769

Description

Vutiglabridin (HSG4112) is a novel, brain-penetrant racemic modulator of mitochondrial paraoxonase 2 (PON2). This optimized Glabridin analogue shows efficacy in preclinical models, ameliorating MPTP-induced neurodegeneration in Parkinson's disease mice and MPP⁺-induced cytotoxicity in SH-SY5Y cells. It is also in clinical Phase 2 trials for obesity.

Research Area

Immunology & Inflammation, Infectious Disease & Virology, Metabolism Research, Molecular Biology

Key Properties

• CAS Number: 1800188-47-9
• MW: 354.44
• Purity: 99.07%
• Formula: C₂₂H₂₆O₄
• SMILES: CC1(C)OC2=C(C3=C(CC(CO3)C4=C(O)C=C(OCC)C=C4)C=C2)CC1
• Target: PPAR,Others,Phosphatase,Antibacterial,ROS
• Solubility: DMSO:10 mg/mL (28.21 mM)

Bioactivity

• In Vivo:
  Vutiglabridin (orally administered with 10, 30, or 100 mg/kg dose for 6 weeks) dose-dependently reduces body weight and normalizes obesity-related parameters in high-fat diet (HFD)-induced obese mice. Led to significant dose-dependent body weight reduction by 4.0 g (8.3%), 10 g (21%), and 19 g (40%), respectively, compared to the 48.1 g body weight of HFD-induced obese mice administered with only the vehicle at 10, 30, and 100 mg/kg. Vutiglabridin fully reverses adiposity in HFD-induced obese mice in a dose-dependent manner.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

HSG 4112, HSG4112, HSG-4112, LMPTP, PON2, Vutiglabridin

Compound Identifiers

PubChem CID

118204185